Q1 2018 13F Holders as of 3/31/2018
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62.2M
-
Number of holders
-
67
-
Total 13F shares, excl. options
-
11.9M
-
Shares change
-
+125K
-
Total reported value, excl. options
-
$103M
-
Value change
-
-$12M
-
Number of buys
-
47
-
Number of sells
-
-28
-
Price
-
$8.59
Significant Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q1 2018
80 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 as of Q1 2018.
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) has 67 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 11.9M shares
of 62.2M outstanding shares and own 19.2% of the company stock.
Largest 10 shareholders include FMR LLC (3.17M shares), EcoR1 Capital, LLC (1.08M shares), FARALLON CAPITAL MANAGEMENT LLC (1.01M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1M shares), Pharmstandard International S.A. (982K shares), BlackRock Inc. (687K shares), VANGUARD GROUP INC (524K shares), BVF INC/IL (406K shares), Cormorant Asset Management, LP (382K shares), and MILLENNIUM MANAGEMENT LLC (321K shares).
This table shows the top 67 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.